Showing 5551-5560 of 10571 results for "".
- National Psoriasis Foundation Launches Patient-centered Research Platformhttps://practicaldermatology.com/news/national-psoriasis-foundation-launches-patient-centered-research-platform/2458902/Patients with psoriasis and psoriatic arthritis can contribute directly to the future of research into these chronic, systemic autoimmune diseases through the National Psoriasis Foundation’s patient-centered research network called Citizen Pscientist. This online, interactive community, all
- Galderma Receives FDA Approval for Epiduo Forte for Acnehttps://practicaldermatology.com/news/galderma-receives-fda-approval-for-epiduo-forte-for-acne/2458909/The FDA approved Galderma’s antibiotic-free Epiduo® Forte (adapalene and benzoyl peroxide) Gel, 0.3%/2.5%, for the once-daily, topical treatment of acne vulgaris. Epiduo Forte Gel is the first combination of these strengths of the retinoid, adapalene, and benzoyl peroxide, developed for
- Heliocare Earns NSF Good Manufacturing Practice Registration For IFC Manufacturing Facilityhttps://practicaldermatology.com/news/heliocare-earns-nsf-good-manufacturing-practice-registration-for-ifc-manufacturing-facility/2458911/Ferndale Healthcare, Inc.’s IFC manufacturing facility for its Heliocare® brand is now a Good Manufacturing Practices (GMP) facility registered by NSF International, an independent organization recognized as the world leader in standards development, product certification, ed
- Restylane Lyft Approved for Cheek Augmentation and Midface Contour Deficiencieshttps://practicaldermatology.com/news/restylane-lyft-approved-for-cheek-augmentation-and-midface-contour-deficiencies/2458917/The FDA approved Galderma's Restylane Lyft for cheek augmentation and the correction of age-related midface contour deficiencies in patients over the age of 21. Restylane Lyft, formerly marketed as Perlane-L, is an injectable gel used to increase volume and smooth wrinkles in the face. With t
- DermatologistOnCall Launches New Mobile Apphttps://practicaldermatology.com/news/dermatologistoncall-launches-new-mobile-app/2458919/DermatologistOnCall launched a new mobile app that it says enables patients to quickly and easily start and complete an online visit with a board-certified dermatologist. The app is free and works with Apple's iPhones and iPads, and Android phones and tablets. "Our new mobile app
- Allergan to Acquire Kytherahttps://practicaldermatology.com/news/allergan-to-acquire-kythera/2458927/Allergan has entered into a definitive agreement to acquire Kythera Biopharmaceuticals in a cash and stock transaction valued at $75 per share, or approximately $2.1 billion. Once the transaction is complete, Kythera’s recently approved Kybella (deoxycholic acid) will be part of an aestheti
- Association of Dermatology Administrators and Managers Names Alice Hyman “Practice Manager of the Year”https://practicaldermatology.com/news/association-of-dermatology-administrators-and-managers-names-alice-hyman-practice-manager-of-the-year/2458966/The Association of Dermatology Administrators and Managers (ADAM) named Alice Hyman of Advanced DermCare in Danbury, CT, the recipient of this year’s Practice Manager of the Year award. She was recognized at the 23rd annual ADAM meeting in San Francisco. Ms. Hyma
- Provectus Biopharmaceuticals' Data on PV-10 to Be Presented at HemOnc Todayhttps://practicaldermatology.com/news/provectus-biopharmaceuticals-data-on-pv-10-to-be-presented-at-hemonc-today/2458972/Provectus Biopharmaceuticals, Inc., a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus"), announced that Dr. Sanjiv Agarwala will present data on PV-10, the Company's novel investigational drug for cancer, at the HemOnc Today Melanoma and Cutaneous
- Dermira Presents Clinical Data for DRM01 Acne Programhttps://practicaldermatology.com/news/dermira-presents-clinical-data-for-drm01-acne-program/2458981/Dermira, Inc. presented clinical data from its DRM01 Phase 2a trial in patients with facial acne vulgaris. The primary endpoints in this trial, the changes from baseline in inflammatory and non-inflammatory lesion counts and an improvement in the Investigator's Global Assessment (IGA) of acne
- Cipher Pharmaceuticals appoints Lynne Bulger as Vice President, Medical Affairshttps://practicaldermatology.com/news/cipher-pharmaceuticals-appoints-lynne-bulger-as-vice-president-medical-affairs/2459022/Cipher Pharmaceuticals Inc. appointed Lynne Bulger as Vice President, Medical and Clinical Affairs to lead the Company's clinical development and medical affairs efforts for current and new pipeline products. Ms. Bulger has 27 years of experience in drug development in the pharmaceuti